- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Review of TA879.
- Process:
- STA Standard
- ID number:
- 6680
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 19 February 2026 - 16 March 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Daiichi Sankyo (trastuzumab deruxtecan)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Black Health Agency for Equality
- Cancer Black Care
- Cancer 52
- GIST Cancer UK
- GUTS UK
- Heartburn Cancer UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Ochre
- OG Support
- OPA Cancer Charity Oesophageal and Gastric Support
- PAWS GIST Clinic
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Anaesthetists of Great Britain and Ireland
- Association of Cancer Physicians
- Association of Surgeons of Great Britain and Ireland
- Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
- BASO ~ The Association for Cancer Surgery
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society of Gastroenterology
- Cancer Research UK
- Primary Care Society for Gastroenterology
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons of England
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox (irinotecan)
- Bristol Myers Squibb (paclitaxel)
- Genus Pharmaceuticals (paclitaxel)
- Hospira (docetaxel, irinotecan, paclitaxel)
- Medac pharma (irinotecan)
- Pfizer (irinotecan)
- Seacross Pharmaceuticals (docetaxel, irinotecan, paclitaxel)
- Servier Laboratories (irinotecan, trifluridine–tipiracil)
- Sun Pharma (irinotecan)
- Teva UK (paclitaxel)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 16 February 2026 | In progress. Draft scope consultation issued. |
For further information on our processes and methods, please see our CHTE processes and methods manual